[EN] AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFOR [FR] INHIBITEUR DU AHR, SON UTILISATION ET SON PROCÉDÉ DE PRÉPARATION [ZH] AhR抑制剂及其用途和制备方法
[EN] PYRANO[4,3-B]L NDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD)<br/>[FR] DÉRIVÉS DE PYRANO [4,3-B] INDOLE EN TANT QUE MODULATEURS D'ALPHA-1-ANTITRYPSINE POUR TRAITER UNE DÉFICIENCE EN ALPHA-1-ANTITRYPSINE (AATD)
申请人:VERTEX PHARMA
公开号:WO2021203014A1
公开(公告)日:2021-10-07
Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)
IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS
申请人:Incyte Holdings Corporation
公开号:US20160326178A1
公开(公告)日:2016-11-10
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Imidazotriazines and imidazopyrimidines as kinase inhibitors
申请人:Incyte Corporation
公开号:US07767675B2
公开(公告)日:2010-08-03
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Imidazotriaines and imidazopyrimidines as kinase inhibitors
申请人:Incyte Corporation
公开号:US10738052B2
公开(公告)日:2020-08-11
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.
Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
申请人:POLYTHERICS LIMITED
公开号:US10835616B2
公开(公告)日:2020-11-17
The invention relates to novel conjugating reagents capable of reaction with at least one nucleophile present in a peptide or protein, which contain at least one leaving group which is lost on reaction with said nucleophile, in which the leaving group includes a portion —(CH2CH2O)n—, in which n is a number of six or more; and novel processes for the preparation of conjugates containing peptides or proteins made using such reagents.